drugset / Trial / NCT04241159

Study to Explore the Safety and Feasibility of Allogeneic Young Plasma Infusion in Older Adults

NCT04241159 ↗

Non-randomizedParallel-groupOpen-labelSupportive care

Summary

Evaluate the feasibility of administering plasma (PF24) acquired from donors of a young chronological age intravenously to older adults at WFBMC while also exploring its effects on age-related functional decline

Timeline

Start
2020-05
Primary completion
2020-08
Completion
2020-08

Outcome

Outcome not reported

Stopped: “Protocol required revisions and application was withdrawn from the IRB.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Allogeneic Young Plasma Unknown 250 ml Intravenous

Indications